CytoMed Therapeutics Limited (GDTC)

Revenue by Segment

Financials in millions SGD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Immune Cell Therapy	860.85K	503.37K	507.74K	1.00	113.84K
Immune Cell Therapy Growth	71.02%	-0.86%	50773500.00%	-100.00%	91.43%
Total	860.85K	503.37K	507.74K	1.00	113.84K
Total Growth	71.02%	-0.86%	50773500.00%	-100.00%	91.43%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 20, 2026

Data Sources Report a data error